These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34295963)

  • 21. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy.
    Chen S; Peng A; Chen M; Zhan M
    Front Oncol; 2022; 12():1093240. PubMed ID: 36741735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
    Xuan C; Hu R
    ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.
    Lu X; Miao L; Gao W; Chen Z; McHugh KJ; Sun Y; Tochka Z; Tomasic S; Sadtler K; Hyacinthe A; Huang Y; Graf T; Hu Q; Sarmadi M; Langer R; Anderson DG; Jaklenec A
    Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle-Mediated STING Activation for Cancer Immunotherapy.
    Li Y; Li X; Yi J; Cao Y; Qin Z; Zhong Z; Yang W
    Adv Healthc Mater; 2023 Jul; 12(19):e2300260. PubMed ID: 36905358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A next-generation STING agonist MSA-2: From mechanism to application.
    Yang J; Luo Z; Ma J; Wang Y; Cheng N
    J Control Release; 2024 Jul; 371():273-287. PubMed ID: 38789087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STING Activation and its Application in Immuno-Oncology.
    Lian Y; Duffy KJ; Yang J
    Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A biodegradable pH and glutathione dual-triggered drug delivery system based on mesoporous silica, carboxymethyl chitosan and oxidized pullulan.
    Rui Q; Gao J; Yin ZZ; Li J; Cai W; Wu D; Kong Y
    Int J Biol Macromol; 2023 Jan; 224():1294-1302. PubMed ID: 36306897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
    Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
    J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
    Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
    Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
    Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
    Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STING activation in cancer immunotherapy.
    Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
    Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.
    Zhang J; Yu S; Peng Q; Wang P; Fang L
    Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
    Garland KM; Sheehy TL; Wilson JT
    Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.
    Koshy ST; Cheung AS; Gu L; Graveline AR; Mooney DJ
    Adv Biosyst; 2017 Feb; 1(1-2):. PubMed ID: 30258983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitizing Tumors to Immune Checkpoint Blockage via STING Agonists Delivered by Tumor-Penetrating Neutrophil Cytopharmaceuticals.
    Hao M; Zhu L; Hou S; Chen S; Li X; Li K; Zhu N; Chen S; Xue L; Ju C; Zhang C
    ACS Nano; 2023 Jan; ():. PubMed ID: 36595464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. M335, a novel small-molecule STING agonist activates the immune response and exerts antitumor effects.
    Zhao M; Fan W; Wang Y; Qiang P; Zheng Z; Shan H; Zhang M; Liu P; Wang Y; Li G; Li M; Hong L
    Eur J Med Chem; 2024 Jan; 264():116018. PubMed ID: 38091891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.